PT-141 (Bremelanotide) is a synthetic analog of the endogenous peptide hormone alpha-MSH (alpha-melanocyte-stimulating hormone), acting as an agonist at melanocortin receptors MC3R and MC4R. It is derived from Melanotan II (MT-II) but lacks the cyclic structure, and has a different receptor selectivity profile. Bremelanotide received FDA approval in 2019 (as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women, making it one of the few melanocortin receptor agonists with clinical drug status.
Unlike MT-2, PT-141 does not cause significant skin pigmentation changes because it has reduced MC1R activity. Its primary activity is through MC3R and MC4R in the CNS, producing effects on sexual function research through central neurological pathways rather than peripheral vascular mechanisms.
Third-party tested · Lot-specific COA · US domestic shipping 24–48h
Buy PT-141 (Bremelanotide) Now →| Purity | ≥99% (HPLC verified, third-party) |
| Molecular Weight | 1,025.2 Da |
| Appearance | White to off-white lyophilized powder |
| Storage | –20°C long-term; 4°C up to 14 days after reconstitution |
| Lot Number | OL-2026-015 |
| Format | Lyophilized powder, sealed vial |
| Certificate of Analysis | Lot-specific COA included with every order |
| Intended Use | In vitro laboratory research only |
| Regulatory Status | FDA-approved (Vyleesi®) — research reference compound |
| Receptor | MC3R and MC4R agonist (reduced MC1R vs MT-2) |
Research Use Disclaimer: PT-141 (Bremelanotide) is sold strictly for in vitro laboratory research purposes only. Not for human consumption, veterinary use, or clinical application. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.